{"name":"Glenmark Pharmaceuticals Ltd. India","slug":"glenmark-pharmaceuticals-ltd-india","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Diclofenac Sodium gel, 1%","genericName":"Diclofenac Sodium gel, 1%","slug":"diclofenac-sodium-gel-1","indication":"Topical treatment of localized pain and inflammation in musculoskeletal conditions (e.g., osteoarthritis, rheumatoid arthritis, sprains, strains)","status":"marketed"},{"name":"Voltaren® Gel","genericName":"Voltaren® Gel","slug":"voltaren-gel","indication":"Topical relief of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","status":"marketed"},{"name":"Protopic® ointment, 0.1%","genericName":"Protopic® ointment, 0.1%","slug":"protopic-ointment-0-1","indication":"Atopic dermatitis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"GRC 17356","genericName":"GRC 17356","slug":"grc-17356","indication":"Other","status":"phase_2"},{"name":"DYMISTA nasal spray","genericName":"DYMISTA nasal spray","slug":"dymista-nasal-spray","indication":"Allergic rhinitis (seasonal and perennial)","status":"phase_3"},{"name":"Placebo of Tacrolimus Ointment","genericName":"Placebo of Tacrolimus Ointment","slug":"placebo-of-tacrolimus-ointment","indication":"Prevention of organ rejection in transplant patients","status":"phase_3"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Elidel® (pimecrolimus) Cream","genericName":"Elidel® (pimecrolimus) Cream","slug":"elidel-pimecrolimus-cream","indication":"Atopic dermatitis (eczema) in patients ≥2 years of age","status":"phase_3"},{"name":"Placebo of Pimecrolimus Cream, 1%","genericName":"Placebo of Pimecrolimus Cream, 1%","slug":"placebo-of-pimecrolimus-cream-1","indication":"Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions","status":"phase_3"}]}],"pipeline":[{"name":"Diclofenac Sodium gel, 1%","genericName":"Diclofenac Sodium gel, 1%","slug":"diclofenac-sodium-gel-1","phase":"marketed","mechanism":"Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of application.","indications":["Topical treatment of localized pain and inflammation in musculoskeletal conditions (e.g., osteoarthritis, rheumatoid arthritis, sprains, strains)","Post-traumatic inflammation and pain relief"],"catalyst":""},{"name":"GRC 17356","genericName":"GRC 17356","slug":"grc-17356","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Voltaren® Gel","genericName":"Voltaren® Gel","slug":"voltaren-gel","phase":"marketed","mechanism":"Voltaren Gel is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce local inflammation and pain at the site of application.","indications":["Topical relief of pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","Acute pain relief from minor sprains, strains, and contusions"],"catalyst":""},{"name":"DYMISTA nasal spray","genericName":"DYMISTA nasal spray","slug":"dymista-nasal-spray","phase":"phase_3","mechanism":"DYMISTA is a nasal spray combining azelastine (a selective H1-receptor antagonist) and fluticasone propionate (a corticosteroid) to reduce allergic rhinitis symptoms through dual anti-inflammatory and antihistamine action.","indications":["Allergic rhinitis (seasonal and perennial)"],"catalyst":""},{"name":"Elidel® (pimecrolimus) Cream","genericName":"Elidel® (pimecrolimus) Cream","slug":"elidel-pimecrolimus-cream","phase":"phase_3","mechanism":"Pimecrolimus is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.","indications":["Atopic dermatitis (eczema) in patients ≥2 years of age","Short-term and intermittent long-term treatment of mild to moderate atopic dermatitis"],"catalyst":""},{"name":"Placebo of Pimecrolimus Cream, 1%","genericName":"Placebo of Pimecrolimus Cream, 1%","slug":"placebo-of-pimecrolimus-cream-1","phase":"phase_3","mechanism":"This is a placebo formulation with no active pharmacological mechanism.","indications":["Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions"],"catalyst":""},{"name":"Placebo of Tacrolimus Ointment","genericName":"Placebo of Tacrolimus Ointment","slug":"placebo-of-tacrolimus-ointment","phase":"phase_3","mechanism":"Tacrolimus ointment is an immunosuppressant that works by inhibiting calcineurin, a protein necessary for T-cell activation.","indications":["Prevention of organ rejection in transplant patients"],"catalyst":""},{"name":"Protopic® ointment, 0.1%","genericName":"Protopic® ointment, 0.1%","slug":"protopic-ointment-0-1","phase":"phase_3","mechanism":"Protopic ointment, 0.1% works by inhibiting the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) to reduce inflammation.","indications":["Atopic dermatitis","Severe psoriasis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-03","type":"pipeline","source":"ET Now","summary":"Trump Tariff on Pharma: Glenmark, Sun Pharma face maximum impact as US announces 100% tariff on branded drugs - ET Now","headline":"Trump Tariff on Pharma: Glenmark, Sun Pharma face maximum impact as US announces 100% tariff on branded drugs","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"Indian Pharma Post","summary":"Glenmark Pharmaceuticals accelerates U.S. strategy with direct RYALTRIS distribution - Indian Pharma Post","headline":"Glenmark Pharmaceuticals accelerates U.S. strategy with direct RYALTRIS distribution","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNZ0NhYTR0aGNmVy1ob1otSEY4a0I0eXI0M2tzNEM3bHREbGlJSnpTSUFPeEtoaUtkV2xqano1eHVydzk0NmNwR2JrR0lfdGVOQWdDN0loREtOUi1DNVpwQXRQNkFDRkx0RjhGX19kd01HNGJpTGZaUFI4N29SUVNBR2cwRzdRVEFFQS1ZRF82VDhJcnBPMDlOYnJkQ1JYYW9weWVQSjgwM2VzLXFtdVViczRLUG1TVGNZSWg1VDk4Yw?oc=5","date":"2026-03-27","type":"pipeline","source":"AD HOC NEWS","summary":"Glenmark Pharmaceuticals Stock: Indian Pharma Player Eyes Growth Amid Technical Strength and Sector - AD HOC NEWS","headline":"Glenmark Pharmaceuticals Stock: Indian Pharma Player Eyes Growth Amid Technical Strength and Sector","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-24","type":"pipeline","source":"The Economic Times","summary":"Glenmark Pharma may outperform amid market correction; technicals turn positive: Ruchit Jain - The Economic Times","headline":"Glenmark Pharma may outperform amid market correction; technicals turn positive: Ruchit Jain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQMkkzLXR6SUFJSGpBNzBURHg1bVhjODI3TW5sMWVBeXFTdUdSZEZlRDY0RDctWW9NMTl0U3BSMzJ6V1RVclUzWWtrQU15YUJtUnllNm95R0E1X1YzVEJJUmtkVThCNnlzYUdHeEp5Q29ndW92Y2RnNjNoamFDeHBrLTRONnoxdkVNcFN1R2tTck5DREV6bHM2RngtcUhEeGZvMWF2TVpuWmtyX3BEcTh3WHBmTHFLRWRuUG94cEhRRktyWFo5bGwwczBKelBQWXQwZzFYdkF2emt5Tzl6ZlpsU09EY2xUTklHZlB1NzFSQUhtRkVS?oc=5","date":"2026-03-16","type":"pipeline","source":"Whalesbook","summary":"Glenmark Pharma US Unit Prepares to Launch New Injectable for $50.7M Market - Whalesbook","headline":"Glenmark Pharma US Unit Prepares to Launch New Injectable for $50.7M Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPNGt4MkczNmhycTRYUWVaVVctc2kyMi1kWmJ1Z2pRRW94cml3anZncG14RTBJV3ZkTXBpWTVQdWlnci1GM090YUpUd3Z5aEVzaVN5QmtabEdMR1cwclBSbWJaR0s0dktzN2htZGM5WUo4SmpCclVzYXowVnU3V3lhQzZqMUtZOERzZjJNVlpZWnZCYjBLcEh0eGlkMjdSNFIxdXkxQUdRamFxUUFGM013NFFnLTJaTlR6a3VNVjNXaU1QVU1ZcU9lZ19oREJ2OGhJOGVVZlAwZkhxaU02ZWhjbUJ3?oc=5","date":"2026-02-03","type":"regulatory","source":"reuters.com","summary":"Indian drugmaker Mankind Pharma posts higher quarterly profit on strong chronic drugs demand - reuters.com","headline":"Indian drugmaker Mankind Pharma posts higher quarterly profit on strong chronic drugs demand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPamVkem9vaTRQemUyNmIxOVEySHVLVEZmazhLMWVkRFdCbjF0VllOd0ZNcEVGTmQ0YzBZNHR5c0drTktmbVFjYlY2RnQySEZlcU1OVEJHTGtZdG5HME1rWHdzTlo2alRPQTRVekE5TUZHWGhsYlRxejUwZV9vd0lBTFVDVTN2LWVieFBmaWF1NmhGYmVDSHgxMTFJYndpU3FXelRHUDdwbnNWd1BIVjFaQnd0NWhHTTNCWTZBeTlfZ3JGak9iWkl0ejVUUjdEWWVTbHhDOXdpVWdZRElmXzVzRVd4TkViRTFHMC1fQm5jVXh0TEM1SmxSVWZB0gH_AUFVX3lxTFA3cG1pSVVOU3gzNnlkRTdTRHdCaG1nM2tGaDV2MVhRaVg1WkNjZml1ZGV4aFc5THdBQ1daU2pvdm9ZMjhPbFhzalg4UGtHT244NWJuS0NQX1lIbEx6ajlhU1hqemtaeldkUXBVLUxrOXhHRjlMMnFNWGdJblRUY1B3U2ZxS0ZVRWljNENqMm14bUlBWjBKUmJyY1E3clllUFpiRlZ6dkdGQmliUGhXclR0a08xMVV3NFk1ZlZKMHVZb0lKTW5HNmtrWmJCQlRkRTZsOTg5OHJIaktZcGRZa1FEMUVZNjlISXdkYVVoNHFzNmtmZklubkxRV3laTjJHSQ?oc=5","date":"2025-11-19","type":"earnings","source":"simplywall.st","summary":"Glenmark Pharmaceuticals Limited Just Beat Revenue By 16%: Here's What Analysts Think Will Happen Next - simplywall.st","headline":"Glenmark Pharmaceuticals Limited Just Beat Revenue By 16%: Here's What Analysts Think Will Happen Next","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNdmZtYlNHQ2dfN19MUjZpZlFrNzBJTXVNNEpiS0FmV3N5ZVBrczNmMmZuSHNIZk5ZSTJaeU9McThtU0JIaEptY0lGOFJ5S2dlckJuVlFINHhwRlhWMXNsX2ltU2JEd201T09EYWhfRFhFa0ozUTg3aEJaa0s2QWlTTVc1U3ZGdGNFZTFfaVc0ODNDaXRpOTNGT2RRUDdyaWw4NDRTQUZOOE96cUxHT0pJY195VVFub29pemI1b2NKTlh3YkdmVGJNMjhWcFRwOTBXQTRpQlBkTzZPNHV5eHhLQg?oc=5","date":"2025-11-14","type":"regulatory","source":"reuters.com","summary":"India's Glenmark posts higher quarterly profit on strong demand in N.America, Europe - reuters.com","headline":"India's Glenmark posts higher quarterly profit on strong demand in N.America, Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxORFZPU2pNNHl0cVUzaHo0cms0a3ZNX29VYmpmYUtPN0RUMTdPTU54Y1dCelJYbGMzTVdUaGpzNzNiVi1EXzBaNXpka0NTZHBHWWlZSERhcEFxeXFEMVRIdW13bXEwdnlwbkNXaG9vaDF4M3ZGcWVTMkh3Zm5rWEc4V3V4LVJTYTFKWGhWYVlIY3dudGNRZWpsNDBtcUJlLUczLVJIWUgxSndwTC1hLTlj?oc=5","date":"2025-09-24","type":"deal","source":"Fierce Pharma","summary":"In potential $1.1B deal, Glenmark grabs certain rights to Hengrui's ADC rival to Enhertu - Fierce Pharma","headline":"In potential $1.1B deal, Glenmark grabs certain rights to Hengrui's ADC rival to Enhertu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQMVk5eEgzM1I5VGJGQTdlU2VtcWN4ZWNDQW9Jc1IxaGlZb0RBQ0RBQ1pLeUZoMjRodm1Zd3ZFYmlnSDlYSGFLUEtfZHd6c0NnWnR0RWRmTmJDSTFCb2pGamcyWUp4N21ub1Q0UDBtcUNLbWk4ZEtaZzFjMVZ1d3loYkc2NElERU5pbGp2cmc4X191Sm9JSDBBNnY1LXlOVEY2UFQtVXR1c2hKck5pV3BoM0t6eEV5QmI0ZDdVV3JCX05HVDQyaFRVSEctaHNLaFM4NkM1ZnQyWm1PTFhTSk1HYnFvOU9CRkh5WVptNVVpSXNoWVY1dE9tc2xoN3ZzbVZwM0dkQUtZVmFKX0Yzd3BUOG1R?oc=5","date":"2025-09-05","type":"trial","source":"PR Newswire","summary":"Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer - PR Newswire","headline":"Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Ca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFA4STVQM2g0eFVPUnFOaExpU0NpcXpmb1VYcXBpX1d2MnFEbG1pVmYzU0x5WUU3TEx1b09xWm5STTd1aUNVZUU0TnBUVFlJRlE2Y1FmQTZpOVp3RUZKU2k2NnNMdmhyYVBSQVNORjE5WUcxWElISE1mREJB?oc=5","date":"2025-07-28","type":"regulatory","source":"ProPublica","summary":"The FDA Is Cracking Down on an Indian Drugmaker Investigated by ProPublica Last Year - ProPublica","headline":"The FDA Is Cracking Down on an Indian Drugmaker Investigated by ProPublica Last Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNamVvTlNIMlRIOURHQnY2UEtYYmVibmRGbDlSOGxFVTAtZ2I1ckN5R0FoeTVORjBSN0Z6bkNBMXBUS2N5VWFzbXdYVnlrUHJBVnNGeU1KYTM4czhLNTZPa3RpMlZSSFlJNC1LdGVmRGxiLV9QV28tRUtzM2lKMGJ3MFJDckpEd05VaEN3?oc=5","date":"2025-07-10","type":"pipeline","source":"sg.finance.yahoo.com","summary":"India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact - sg.finance.yahoo.com","headline":"India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"marketed":2,"phase_2":1,"phase_3":5},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}